Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Abstract CT188: ICT01, an anti-butyrophilin 3A targeted mAb activating g9d2 T cells, induces immune remodeling of the tumor microenvironment and clinical responses in combination with pembrolizumab in patients with advanced solid tumors who failed prior checkpoint inhibitor therapy: EVICTION Trial

Cancer Res (2022) 82 (12_Supplement): CT188.

https://doi.org/10.1158/1538-7445.AM2022-CT188

Published: 15 June 2022

View article titled, Abstract CT188: ICT01, an anti-butyrophilin 3A targeted mAb activating g9d2 T cells, induces immune remodeling of the tumor microenvironment and clinical responses in combination with pembrolizumab in patients with advanced solid tumors who failed prior checkpoint inhibitor therapy: EVICTION Trial

Journal Articles

Abstract 1813: DIACC2010, a selective inhibitor of KIF20A

Yves COLLETTE, Rémy CASTELLANO, Michel AURRAND-LIONS, Hélène SICARD, Norbert VEY, Cécile BOUGERET

Cancer Res (2022) 82 (12_Supplement): 1813.

https://doi.org/10.1158/1538-7445.AM2022-1813

Published: 15 June 2022

View article titled, Abstract 1813: DIACC2010, a selective inhibitor of KIF20A

Journal Articles

Abstract CT034: Activation of the antitumor immune response of gamma9delta2 T cells in patients with solid or hematologic malignancies with ICT01, a first-in-class, monoclonal antibody targeting butyrophilin 3A: The EVICTION study

Aurelien Marabelle, Christiane Jungels, Johann De Bono, Norbert Vey, Martin Wermke, Elena Garralda, Steven Le Gouill, Patricia LoRusso, Aude De Gassart, Emmanuel Valentin, Patrick Brune, Marina Iche, Daniel Olive, Paul A. Frohna

Cancer Res (2021) 81 (13_Supplement): CT034.

https://doi.org/10.1158/1538-7445.AM2021-CT034

Published: 01 July 2021

View article titled, Abstract CT034: Activation of the antitumor immune response of gamma9delta2 T cells in patients with solid or hematologic malignancies with ICT01, a first-in-class, monoclonal antibody targeting butyrophilin 3A: The EVICTION study

Journal Articles

JAM-C Expression as a Biomarker to Predict Outcome of Patients with Acute Myeloid Leukemia—Response

Maria De Grandis, Stéphane J.C. Mancini, Norbert Vey, Michel Aurrand-Lions

Cancer Res (2018) 78 (21): 6342–6343.

https://doi.org/10.1158/0008-5472.CAN-18-0834

Published: 01 November 2018

View article titled, JAM-C Expression as a Biomarker to Predict Outcome of Patients with Acute Myeloid Leukemia—Response

Journal Articles

JAM-C Identifies Src Family Kinase-Activated Leukemia-Initiating Cells and Predicts Poor Prognosis in Acute Myeloid Leukemia

Maria De Grandis, Florence Bardin, Cyril Fauriat, Christophe Zemmour, Abdessamad El-Kaoutari, Arnauld Sergé, Samuel Granjeaud, Laurent Pouyet, Camille Montersino, Anne-Sophie Chretien, Marie-Joelle Mozziconacci, Remy Castellano, Ghislain Bidaut, Jean-Marie Boher, Yves Collette, Stéphane J.C. Mancini, Norbert Vey, Michel Aurrand-Lions

Cancer Res (2017) 77 (23): 6627–6640.

https://doi.org/10.1158/0008-5472.CAN-17-1223

Published: 30 November 2017

View article titled, JAM-C Identifies Src Family Kinase-Activated Leukemia-Initiating Cells and Predicts Poor Prognosis in Acute Myeloid Leukemia

Includes: Supplementary data

Journal Articles

Abstract 4140: Identification of a selective MKLP2/KIF20A inhibitor with high in-vivo antitumor activity

Yves Collette, Stephanie Miserey-Lenkei, Catherine Guillou, Denis Carniato, Bernard Pau, Bruno Goud, Norbert Vey, Cecile E. Bougeret

Cancer Res (2017) 77 (13_Supplement): 4140.

https://doi.org/10.1158/1538-7445.AM2017-4140

Published: 01 July 2017

View article titled, Abstract 4140: Identification of a selective MKLP2/KIF20A inhibitor with high in-vivo antitumor activity

Journal Articles

Frequency and Dynamics of Leukemia-Initiating Cells during Short-term Ex Vivo Culture Informs Outcomes in Acute Myeloid Leukemia Patients

Emmanuel Griessinger, Fernando Anjos-Afonso, Jacques Vargaftig, David C. Taussig, François Lassailly, Thomas Prebet, Véronique Imbert, Marielle Nebout, Norbert Vey, Christian Chabannon, Andrew Filby, Frederic Bollet-Quivogne, John G. Gribben, Jean-François Peyron, Dominique Bonnet

Cancer Res (2016) 76 (8): 2082–2086.

https://doi.org/10.1158/0008-5472.CAN-15-2063

Published: 14 April 2016

View article titled, Frequency and Dynamics of Leukemia-Initiating Cells during Short-term Ex Vivo Culture Informs Outcomes in Acute Myeloid Leukemia Patients

Includes: Supplementary data

Journal Articles

Abstract CT113: A phase III, multicenter, randomized study evaluating the efficacy and safety and efficacy of erythrocyte encapsulated l-asparaginase (Ery001) versus native l-asparaginase (L-asp) in combination with COOPRALL regimen in patients with first relapse of acut

Yves Bertrand, Andre Baruchel, Xavier Thomas, Nicolas Blin, Emmanuelle Tavernier, Yves Perel, Norbert Vey, Virginie Gandemer, Iman ElHariry, Yann Godfrin

Cancer Res (2015) 75 (15_Supplement): CT113.

https://doi.org/10.1158/1538-7445.AM2015-CT113

Published: 01 August 2015

View article titled, Abstract CT113: A phase III, multicenter, randomized study evaluating the efficacy and safety and efficacy of erythrocyte encapsulated l-asparaginase (Ery001) versus native l-asparaginase (L-asp) in combination with COOPRALL regimen in patients with first relapse of acut

Journal Articles

Phase I study of CP-4055 (ELACYT^TM), a novel nucleoside analog, in patients with refractory leukemias

Francis Giles, David Rizzieri, Thomas Prebet, Aude Charbonnier, Tove Jacobsen, Marit Sandvold, Kjell Hernes, Norbert Vey

Cancer Res (2007) 67 (9_Supplement): 3185.

Published: 01 May 2007

View article titled, Phase I study of CP-4055 (ELACYTTM), a novel nucleoside analog, in patients with refractory leukemias

Journal Articles

Low levels of pre-treatment O⁶-alkylguanine transferase (AGT) in patients with AML correlate with response to Cloretazine® (VNP40101M) induction therapy

Stanton Gerson, Judy Karp, David Rizzieri, Norbert Vey, Verena Karsten, Frank Giles

Cancer Res (2007) 67 (9_Supplement): 2640.

Published: 01 May 2007

View article titled, Low levels of pre-treatment O6-alkylguanine transferase (AGT) in patients with AML correlate with response to Cloretazine® (VNP40101M) induction therapy

NARROW

Abstract CT188: ICT01, an anti-butyrophilin 3A targeted mAb activating g9d2 T cells, induces immune remodeling of the tumor microenvironment and clinical responses in combination with pembrolizumab in patients with advanced solid tumors who failed prior checkpoint inhibitor therapy: EVICTION Trial

Abstract 1813: DIACC2010, a selective inhibitor of KIF20A

Abstract CT034: Activation of the antitumor immune response of gamma9delta2 T cells in patients with solid or hematologic malignancies with ICT01, a first-in-class, monoclonal antibody targeting butyrophilin 3A: The EVICTION study

JAM-C Expression as a Biomarker to Predict Outcome of Patients with Acute Myeloid Leukemia—Response

JAM-C Identifies Src Family Kinase-Activated Leukemia-Initiating Cells and Predicts Poor Prognosis in Acute Myeloid Leukemia

Abstract 4140: Identification of a selective MKLP2/KIF20A inhibitor with high in-vivo antitumor activity

Frequency and Dynamics of Leukemia-Initiating Cells during Short-term Ex Vivo Culture Informs Outcomes in Acute Myeloid Leukemia Patients

Abstract CT113: A phase III, multicenter, randomized study evaluating the efficacy and safety and efficacy of erythrocyte encapsulated l-asparaginase (Ery001) versus native l-asparaginase (L-asp) in combination with COOPRALL regimen in patients with first relapse of acut

Phase I study of CP-4055 (ELACYT^TM), a novel nucleoside analog, in patients with refractory leukemias

Low levels of pre-treatment O⁶-alkylguanine transferase (AGT) in patients with AML correlate with response to Cloretazine® (VNP40101M) induction therapy

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only